mhra

UK backs modernisation of gene therapy definitions

The MHRA will advance proposed definition changes intended to bring certain synthetic gene therapies and genome-editing treatments within the established advanced therapies framework.

Ersin ÇETİNMDR Auditor
Türkçe oku
Conceptual scientific illustration representing synthetic nucleic acids, genome editing and a regulatory framework
AI-generated conceptual illustration, not a photograph of an actual event.

What Changed

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced government backing for plans to modernise the UK legal definition of gene therapy medicinal products (GTMPs). The proposals aim to give certain synthetic gene therapies and novel genome-editing treatments a clearer route through the established advanced therapies framework.

According to the MHRA, 83% of respondents supported the proposals in a consultation conducted jointly with the Department of Health in Northern Ireland. The agency will now progress legislation to make the definitions more technologically neutral.

Who Is Affected

The proposals primarily concern medicine developers using synthetic genetic material or genome-editing technologies. The MHRA says some emerging products may not fit neatly within existing advanced therapy medicinal product (ATMP) categories.

Consultation participants included pharmaceutical and biotechnology companies, academic institutions, NHS organisations, patient groups and professional bodies. The proposed measure concerns medicinal-product classification, rather than medical-device regulation.

Regulatory and Technical Implications

Once implemented, GTMP classification would depend on whether the active substance contains a recombinant or synthetic nucleic acid that undergoes transcription or translation, or whether the mechanism of action involves sequence-specific genome editing.

The planned amendments to the Human Medicines Regulations 2012 remain subject to international notification procedures and parliamentary approval. They should therefore not be treated as requirements already in force.

The MHRA states that the existing approval process and standards for safety, quality and efficacy will remain unchanged. Medicines already licensed will not need to be reclassified.

Manufacturer Actions

For affected developers, the key developments to monitor are the legislative wording and implementation timing. Classification planning should distinguish the proposed scope from the rules currently in force.

The MHRA expects clearer definitions to help developers understand the regulatory requirements applicable to their products. The announcement does not introduce a new manufacturer submission obligation or specify a compliance deadline.

Confirmed Dates

The UK-wide consultation opened on 11 May 2026 and closed on 22 June 2026. The MHRA press release was published on 19 November 2026.

The DIA-MHRA Global Summit took place in London on 16–17 November 2026. No commencement or implementation date for the definition changes was specified.

Official Source

MHRA press release on GOV.UK: “Government backs modernisation of gene therapy definitions”.

Https://www.gov.uk/government/news/government-backs-modernisation-of-gene-therapy-definitions

Source and related services

Government backs modernisation of gene therapy definitions ↗

Source date: 19/11/2026

This news provides general information and does not replace device-specific legal or conformity assessment advice.

Related news

MHRA records closure of an IDAP UCNA entry →MHRA appoints Steven Davies to lead finance and commercial operations →MHRA publishes field safety notice list for 9–13 November 2026 →
Contact an MDR Expert